Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex
- PMID: 32071837
- PMCID: PMC7012745
- DOI: 10.1002/jmd2.12065
Morquio-B disease: Clinical and genetic characteristics of a distinct GLB1-related dysostosis multiplex
Abstract
Background: Morquio-B disease (MBD) is a distinct GLB1-related dysostosis multiplex involving the trabecular parts of long bones and spine, presenting a mild phenocopy of GALNS-related Morquio-A disease.
Methods: We analyzed 63 (n = 62 published) cases with MBD to describe their clinical, biochemical and genetic features.
Results: Forty-one of 51 cases with informative clinical data had pure MBD including progressive growth impairment, kyphoscoliosis, coxa/genua valga, joint laxity, platyspondyly, odontoid hypoplasia. Ten of 51 had MBD plus neuronopathic manifestations including intellectual/developmental/speech delay, spasticity, ataxia dystonia. Corneal clouding, cardiac valve pathology, hepatosplenomegaly, spinal cord compression were infrequent and atlantooccipital dislocation, cardiomyopathy and cherry red spot were never reported. Urinary glycosaminoglycan and oligosaccharide excretion was consistently abnormal. Keratan sulphate-derived oligosaccharides were only detected using LC-MS/MS-based methods. Residual β-galactosidase activities measured against synthetic substrates were 0%-17%.Among 28 GLB1 variants, W273 L (34/94 alleles) and T500A (11/94 alleles) occurred most frequently. W273L was invariably associated with pure MBD. Pure MBD also was reported in a case homozygous for R201H, and in the majority of cases carrying the T500A variant. Homozygous Y333C and G438E were associated with MBD plus neuronopathic manifestations. T82M, R201H, and H281Y, observed in seven alleles, previously have been found sensitive to experimental chaperones.
Conclusion: Data provide a basis for future systematic collection of clinical, biochemical, morphologic, and genetic data of this ultra-rare condition.
Keywords: dwarfism; literature review; mucopolysaccharidosis; natural history; spondyloepiphyseal dysplasia.
© 2019 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM.
Conflict of interest statement
S.S.‐I. holds The Priest Family Fund for Morquio‐B Research, a UBC‐based stewardship grant. She has received educational grants from Biomarin, Shire, Recordati and she serves/served as PI in clinical trials and postmarketing registries sponsored by Actelion, Biomarin, Shire, Ultragenyx. I.A., N.Y., and E.P. have no conflicts to declare.
References
-
- Regier DS, Tifft CJ. GLB1‐related disorders In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle, WA: University of Washington, Seattle; 2013:1993‐2018. - PubMed
-
- Bonafe L, Cormier‐Daire V, Hall C, et al. Nosology and classification of genetic skeletal disorders: 2015 revision. Am J Med Genet A. 2015;167A(12):2869‐2892. - PubMed
-
- Spranger JW, Brill PM, Nishimura G, Superti‐Furga A, Unger S. Bone Dysplasias. An Atlas of Genetic Disorders of Skeletal Development. 3rd ed New York: Oxford University Press; 2012:565‐594.
-
- Suzuki Y, Nanba E, Matsuda J, Higaki K, Oshima A. β‐Galactosidase deficiency (β‐galactosidosis): GM1 gangliosidosis and Morquio‐B disease In: Beaudet AL, Vogelstein B, Kinzler KW, et al., eds. The Online Metabolic and Molecular Bases of Inherited Disease [Internet]. New York, NY: The McGraw‐Hill Companies, Inc.; 2014.
-
- Morquio L. Sur une forme de dystrophie osseuse familiale. Bull Soc Pediatr. 1929;27(2):145‐152.
LinkOut - more resources
Full Text Sources
